Aptamer technology: a new approach to treat lymphoma?

Youli Zu

Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas, USA

Abstract
Oligonucleotide aptamers are a class of small-molecule ligands. Functionally similar to protein antibodies, aptamers can specifically bind to their targets with high affinity. Biomedical studies have revealed the potential clinical value of aptamer technology for disease diagnosis and targeted therapy. Lymphoma is a group of cancers originating from the lymphatic system. Currently, chemotherapy is the primary treatment for lymphoma, although it may cause serious side effects in patients due to lack of target specificity. Here, we selectively discuss the recent development of potential applications of aptamer technology for precision lymphoma therapy, which are able to not only achieve high therapeutic efficacy but also do not cause off-target side effects.

Keywords: Immunotherapy, Lymphoma, Oligonucleotide aptamer, Precision therapy, Target therapy

1. INTRODUCTION

Aptamers are a new class of small-molecule ligands composed of short, single-stranded RNA or DNA. Target-specific aptamers can be developed through Systematic Evolution of Ligands by Exponential enrichment (SELEX) technology. In contrast to conventional nucleic acid molecular probes, aptamers precisely interact with their targets through structural recognition, a process similar to that of an antigen-antibody reaction. Because oligonucleotide aptamers are chemically synthesized and can specifically bind to their targets with high affinity, they are also referred to as “chemical antibodies.”

Notably, due to their unique physical and chemical properties, aptamers offer several advantages over protein antibodies in biomedical research and clinical applications. Oligonucleotide aptamers (i) can be chemically synthesized at low production costs; (ii) can be easily modified and conjugated with a variety of functional moieties for biomedical and clinical use; (iii) theoretically are not immunogenic in vivo due to their short oligonucleotide nature; and (iv) have the capacity for efficient tissue penetration and fast cell binding. Therefore, as molecular recognition probes, aptamers have been widely studied to develop new approaches for disease diagnosis and target therapy.

Lymphoma is a group of cancers originating from the lymphatic system. Currently, chemotherapy is the primary treatment for lymphoma. Because chemotherapy is not lymphoma cell- or oncogene-specific, it may cause serious side effects and even increase the risk of a second malignancy in patients. To address these clinical challenges, new target therapeutic approaches using aptamer technology have been reported. Recent studies showed that these new approaches can enhance therapy efficacy and also reduce off-target side effects, helping to achieve precision medicine.

2. POTENTIAL APPROACHES OF APTAMER TECHNOLOGY FOR PRECISION LYMPHOMA THERAPY

2.1. Aptamer treatment to prime lymphoma cells for chemotherapy

To target lymphoma cells, we have conducted cell-based SELEX experiments and identified an ssDNA aptamer specifically targeting Maver-1 cells (a cell line of mantle cell lymphoma). Synthetic aptamers were able to specifically bind Maver-1 lymphoma cells with high affinity and subsequently triggered endocytosis of aptamers into the targeted cells. Interestingly, cellular function studies revealed that exposure of Maver-1 cells to aptamers induced S-phase arrest of 40% of the targeted cells (versus 18% baseline). Further investigation demonstrated that aptamer internalization into targeted cells is a prerequisite for S-phase arrest of Maver-1 cells. Findings suggested that aptamer treatment was able to regulate the cell growth cycle and thus control lymphoma cell growth through an unknown cellular signaling mechanism. More importantly, this aptamer-induced S-phase arrest also provided an opportunity to enhance chemotherapy efficacy, particularly by chemotherapeutic agents that selectively kill lymphoma cells at S-phase, such as cytarabine. As expected, in vitro studies indicated that pretreatment by aptamers significantly primed Maver-1 cells for subsequent cytarabine chemotherapy, achieving a synergistic killing effect by reaching cell death rates as high as 61% (versus 13% or 14% induced by aptamer pretreatment alone or cytarabine chemotherapy alone, respectively). This study demonstrated that aptamers do not only...
A CD30 antibody-drug conjugate targets the CD30 receptor, which is a distinct biomarker for the diagnosis of lymphoma cells characterized by high-level expression of the surface receptor. Brentuximab vedotin, containing CD30 aptamer sequences, is a FDA-approved drug for the treatment of refractory large cell lymphoma (ALCL). Although production of antibody-drug conjugates is labor-consuming and costly, the clinical utility of antibody-drug conjugates is limited mainly by ineffective delivery to cells of interest due to lack of cell specificity. Interestingly, both siRNA and aptamers are synthetic oligonucleotides, siRNAs can be covalently or noncovalently conjugated with aptamers to form aptamer-siRNA chimeras for cell-specific gene therapy.

To eliminate adverse toxicity, antibody-drug conjugates have been used clinically for cell-selective chemotherapy. Anaplastic large cell lymphoma (ALCL) is the most common aggressive T-cell lymphoma in children and young adults. ALCL cells are characterized by high-level expression of the surface CD30 receptor, which is a distinct biomarker for diagnosis of the disease and target therapy. Brentuximab vedotin is a CD30 antibody-drug conjugate (brentuximab vedotin) that has been approved to treat refractory ALCL, although production of antibody-drug conjugates is labor-consuming and costly. In contrast, aptamer-drug conjugates can be easily produced through covalently or noncovalently conjugating synthetic aptamer sequences directly with therapeutic agents such as doxorubicin to treat lymphomas. Additionally, aberrant expression of the anaplastic lymphoma kinase (ALK) oncogene has been demonstrated to be a key pathogenic factor for ALCL development. Molecular studies revealed that the silencing of the ALK oncogene by small interfering RNA (siRNA) methods inhibited lymphoma growth. However, the clinical utility of siRNA therapy is limited mainly by ineffective delivery to cells of interest due to lack of cell specificity. Interestingly, both siRNA and aptamers are synthetic oligonucleotides, siRNAs can be covalently or noncovalently conjugated with aptamers to form aptamer-siRNA chimeras for cell-specific gene therapy.

In order to combine chemotherapy and gene therapy designed for ALCL, a cell-selective and oncogene-specific aptamer nanomedicine was investigated, making use of aptamer technology. A nanostructure was initially formulated through programmatic self-assembly of three synthetic complementary oligonucleotides containing aptamer sequences specific for ALCL cells (K299 cell line) and a siRNA sequence specific for the cellular ALK oncogene. Subsequently, the aptamer nanomedicine was generated by a drug self-loading process via intercalation of doxorubicin into the formed nanostructures. Physical, chemical, and biological properties of the formed aptamer nanomedicine were characterized. As expected, functional studies showed that under aptamer guidance, the aptamer nanomedicine binds and then internalizes into targeted ALCL cells. Intracellular delivery of aptamer nanomedicine via endocytosis triggers rapid release of doxorubicin drug payload within the targeted cells for cell-selective chemotherapy. In addition, intracellular delivery of the carried siRNA via macropinocytosis specifically induced cellular ALK oncogene silencing. Concurrently functioning through different therapeutic mechanisms results in additional and synergistic inhibitory effects on ALCL cells (Fig. 2). Furthermore, xenograft animal model studies revealed that upon systemic administration, the aptamer nanomedicine specifically targets and selectively accumulates in the ALCL tumor, but it does not react with off-target tumor in the same mouse. Importantly, the aptamer nanomedicine treatment not only induces higher inhibition in lymphoma tumors but also causes fewer side effects in treated mice as compared to treatment with an equal amount of free doxorubicin. Moreover, aptamer nanomedicine treatment markedly improves the survival rate of treated mice, providing a new method for precision lymphoma therapy. Finally, given that aptamer nanomedicine is composed of biocompatible and biodegradable materials and can be easily produced through programmed design and self-assembly process, it will be highly transformative for clinical use. Notably, the aptamer nanomedicine is a universal platform and can be used to treat different types of cancers by simply replacing the aptamer sequence specific for cells of interest and the siRNA sequence for the underlying pathogenic oncogene.

2.3. Aptamer-engineered natural killer cells for cell-specific immunotherapy

Chimeric antigen receptor (CAR)-T cell technology has been recently approved for cancer immunotherapy and has shown highly promising results. CD30-specific CAR-T cells are also
under investigation to treat lymphomas, including ALCL. However, CAR-T cell therapy has the potential to cause severe cytokine release storms and lethal neurotoxicity. In contrast to T cells, the safety of autologous, allogeneic, and cultured natural killer (NK) cells for adaptive immunotherapy has been demonstrated. More interestingly, NK cells are able to attack cancer cells without prior sensitization or clonal expansion and can induce the death of targeted cancer cells through exocytosis of cytotoxic granules. These unique inherent properties confer high value to NK cells in adaptive cancer immunotherapy. However, due to a lack of cell-specific receptors, NK cells cannot selectively target cancer cells, thus diminishing their immunotherapeutic potential. To render NK cells with target specificity, CAR-NK technology has emerged and its efficacy to treat lymphoma is currently under investigation. Producing CAR-NK cells, however, is labor-intensive and has inherent risks for patients, such as transgene insertional mutagenesis due to genetic manipulation and the viral material involvement required for CAR-NK cell production.

To develop a simple and safe immunotherapy approach, we recently reported an aptamer-engineered NK (ApEn-NK) cell method by taking advantages of aptamer technology. As shown in Figure 3A, a unique aptamer-anchor structure was first chemically synthesized using an aptamer sequence specific for ALCL cells. The ApEn-NK cells were then produced via rapid incubation of naïve NK cells with aptamer-anchor structures, which are rapidly engineered on the NK cell surface through a programmatic anchoring reaction. Specific lymphoma cell binding by ApEn-NK cells, under surface-anchored aptamer guidance, the ApEn-NK cells specifically bind to biomarkers on lymphoma cells and form cell clusters with targeted cells. Specific lymphoma cell killing by ApEn-NK cells. The aptamer-mediated cell binding will result in enhanced killing of targeted cells by ApEn-NK cells, achieving lymphoma-specific immunotherapy without side effects on off-target cells.
programmatic anchoring reaction. It is expected that once equipped with surface-anchored aptamer sequences, the formed ApEn-NK cells will become ALCL cell-specific. Under aptamer guidance, the ApEn-NK cells will specifically bind with lymphoma cells, thus resulting in the selective killing of targeted cells with high efficacy (Fig. 3B and C). The in vitro studies revealed that in cell mixture, ApEn-NK cells specifically bound to and thus formed significantly more cell clusters with lymphoma cells than that observed in the cell mixture of lymphoma and parental NK cells under the same conditions. Subsequent cell killing assays demonstrated that ApEn-NK cells induced significant increases in apoptosis and the death of target lymphoma cells in cell mixtures, as compared to the baseline effect of parental NK cells in cell mixtures containing the same lymphoma cells. In addition, for preclinical validation, primary human naïve NK cells were isolated from peripheral blood of healthy donors and expanded by in vitro culture. Similarly, functional studies showed that the ApEn-NK cells derived from primary human NK cells had the capacity for specific binding to lymphoma cells and enhanced killing of targeted cells in cell mixtures. Notably, because the production process does not involve genomic introduction/alteration or the usage of viral mixtures. Notably, because the production process does not involve genomic introduction/alteration or the usage of viral mixtures. Notably, because the production process does not involve genomic introduction/alteration or the usage of viral mixtures.

3. CONCLUSION AND DISCUSSION

As chemical antibodies, oligonucleotide aptamers can be easily conjugated with different functional molecules per clinical needs for disease diagnosis and treatment. To demonstrate the clinical application capacity of aptamer technology, this article selectivly discussed three potential approaches for precision lymphoma therapy. These studies indicate that logically combining aptamer technology with different therapeutic modalities will allow us to develop new personalized and/or precision therapeutic approaches that have high therapeutic efficacy for lymphoma and low off-target adverse effects in patients. To accelerate the translation of aptamer-mediated clinical applications from bench-side to bedside, close collaboration among scientists, chemists, and clinicians is indispensable. Although some technical challenges remain to be overcome, as more preclinical and clinical studies are conducted, aptamer technology can become a powerful tool in the near future for precision therapy to treat lymphoma, as well as other diseases.

ACKNOWLEDGMENTS

The author would like to thank Dr. Adrienne Winston for her scientific editing of this paper. This study was partially supported by NIH grant R01 CA224304.

REFERENCES

[1] Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990; 346 (6287):818–822.
[2] Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990; 249 (4968):505–510.
[3] Majumder P, Gomes KN, Ulrich H. Aptamers: from bench side research towards patented molecules with therapeutic applications. Expert Opin Ther Pat 2009; 19 (11):1603–1613.
[4] Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov 2010; 9 (7):537–550.
[5] Kanwar JR, Roy K, Kanwar RK. Chimeric aptamers in cancer cell-targeted drug delivery. Crit Rev Biochem Mol Biol 2011; 46 (6): 459–477.
[6] Sun H, Zu Y. Aptamers and their applications in nanomedicine. Small 2015; 11:2352–2364. doi: 10.1002/smll.201403075.
[7] Sun H, Zu Y. A highlight of recent advances in aptamer technology and its application. Molecules 2015; 20:11959–11980.
[8] Xiang D, Zheng C, Zhou SF, et al. Superior performance of aptamer in tumor penetration over antibody: implication of aptamer-based theranostics in solid tumors. Theranostics 2015; 5 (10):1083–1097.
[9] Sun H, Zu Y. Aptamers: versatile molecular recognition probes for cancer detection. Analyst 2016; 141 (2):403–415.
[10] Yang S, Li H, Xu L, et al. Oligonucleotide aptamer-mediated precision therapy of hematological malignancies. Mol Tber Nucleic Acids 2018; 13:164–175. doi: 10.1016/j.omtn.2018.08.023.
[11] Zeng Z, Zhang P, Zhao N, et al. Using oligonucleotide aptamer probes for immunostaining of formalin-fixed and paraffin-embedded tissues. Mod Pathol 2010; 23:1553–1558.
[12] Zeng Z, Parekh P, Li Z, Shi ZZ, Tung CH, Zu Y. Specific and sensitive tumor imaging using biostable oligonucleotide aptamer probes. Theranostics 2014; 4 (9):945–952. doi:10.7150/thno.9246.
[13] Longo G, Fiorani C, Sacchi S, et al. Clinical characteristics, treatment outcome and survival of 36 adult patients with primary anaplastic large cell lymphoma. Haematologica 1999; 84:423–430.
[14] Sizuna J, North C, Stanley J, Winterberg N. Side effects of CHOP in the treatment of non-Hodgkin’s lymphoma. Cancer Nurs 1997; 20: 430–439.
[15] Itoh K, Ohtsu T, Fukuda H, et al. Members of the lymphoma study group of the Japan Clinical Oncology Group (JCOG) Randomized phase II study of biweekly CHOP and dose escalated CHOP with prophylactic use of lenogastim (glycosylated G-CSF) in aggressive non-Hodgkin’s lymphoma: Japanese Clinical Oncology Group Study 9505. Ann Oncol 2002; 13:1347–1355.
[16] Wunderlich A, Kloess M, Reiser M, et al. German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL).Practicality and acute haematological toxicity of 2- and 3-weekly CHOP and CHOP chemotherapy for aggressive non-Hodgkin’s lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Ann Oncol 2003; 14:881–893.
[17] Keefe AD1, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov 2010; 9 (7):537–550. doi: 10.1038/nrd3141.
[18] Zhou J, Rossi J, Aptamers as targeted therapeutics: current potential and challenges. Nat Rev Drug Discov 2017; 16 (6):440. doi: 10.1038/nrd.2017.86.
[19] Nimjee SM, White RR, Becker RC, Sullenger BA. Aptamers as therapeutics. Annu Rev Pharmacol Toxicol 2017; 57:61–79. doi: 10.1146/annurev-pharmtox-011716-104538.
[20] Li H, Yang S, Yu G, et al. Apoptosis and parafin-embedded tissues. Pediatr Hematol Oncol 2013; 30 (6):509–519.
[21] Perkins S, Pickering D, Lowe E, et al. Childhood anaplastic large cell lymphoma: a high incidence of ALK gene rearrangement as determined by immunohistochemical staining and fluorescent in situ hybridisation: a genetic and pathological correlation. Br J Haematol 2005; 131 (5):624–627.
[22] Delsol G, Jaffe ES, Faini B, Swerdlow SH, Campo E, Harris NL, et al. Anaplastic large cell lymphoma (ALCL), ALK positive. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues Lyon: WHO Press; 2008; 312–316.
[23] Younes A, Bartlent NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD-30 positive lymphomas. N Engl J Med 2010; 363:1812–1821.
[24] Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30:2190–2196.
[25] Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL. Look AT: fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 1994; 263:1281–1284.
[26] Dusyter A, Bari RY, Morris SW. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 2001; 20:5623–5637.
[28] Ritter U, Damm-Welk C, Fuchs U, Bohle RM, Borkhardt A, Woessmann W. Design and evaluation of chemically synthesized siRNA targeting the NPM-ALK fusion site in anaplastic large cell lymphoma (ALCL). Oligonucleotides 2003; 13 (5):365–373.

[29] Ito M, Zhao N, Zeng Z, Chang CC, Zu Y. Synergistic inhibition of anaplastic large T-cell Lymphoma cells by combination of ALK gene silence and kinase inhibitor U0126. Cancer Gene Ther 2010; 17:63–44.

[30] Zhao N, Zeng Z, Za Y. Self-assembled aptamer-nanomedicine for targeted chemotherapy and gene therapy. Small 2018; 14 (4): doi: 10.1002/smll.201702103.

[31] Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368 (16):1509–151.

[32] Grover NS, Savoldo B, Barbara. Challenges of driving CD30-directed CAR-T cells to the clinic. BMC Cancer 2019; 19 (1):203:doi: 10.1186/s12885-019-5415-9.

[33] Santomasso B, Bachier C, Westin J, Rervani K, Shpall EJ. The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. Am Soc Clin Oncol Educ Book 2019; 39:433–444. doi: 10.1200/EDBK_238691.

[34] Mackall CL, Miklos DB. CNS endothelial cell activation emerges as a driver of CAR T cell-associated neurotoxicity. Cancer Discov 2017; 7 (12):1371–73.

[35] Rubnitz JE, Inaba H, Ribeiro RC, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010; 28 (6):955–959.

[36] Fang F, Xiao W, Tian Z. NK cell-based immunotherapy for cancer. Semin Immunol 2017; 31:37–54. doi: 10.1016/j.smim.2017.07.009.

[37] Glenke W, Esser R, Priesner C, et al. Advantages and applications of CAR-expressing natural killer cells. Front Pharmacol 2015; 6:21:doi: 10.3389/fphar.2015.00021.

[38] Yang S, Wen J, Li H, et al. Aptamer-engineered natural killer cells for cell-specific adaptive immunotherapy. Small 2019; e1900903:doi: 10.1002/smll.201900903.